Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the therapeutic efficacy and toxicity of the combination
chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian
cancer. The main objective is to test whether the therapeutic intervention benefits the
patient evaluating the number of subjects who are progression-free after 18 months from the
beginning of the first line treatment.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborator:
Mario Negri Institute for Pharmacological Research